Drug Profile
HCV 371
Alternative Names: HCV-371Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator ViroPharma; Wyeth
- Class Antivirals; Indoles; Pyrans
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 11 Aug 2003 Discontinued - Phase-I for Hepatitis C treatment in USA (unspecified route)
- 03 Jan 2003 Phase-I clinical trials in Hepatitis C treatment in USA (unspecified route)